Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huayu Qiangshen Tongbi Formula (HQT) is a traditional Chinese medicine (TCM) herbal decoction developed by the Guangdong Provincial Hospital of Chinese Medicine (also known as the Second Affiliated Hospital of Guangzhou University of Chinese Medicine) for the treatment of rheumatoid arthritis (RA). The formula is composed of ten natural herbs, including Salvia miltiorrhiza (Danshen), Dioscorea nipponica (Chuanshanlong), Astragalus membranaceus (Huangqi), Paeonia lactiflora (Baishao), and Saussurea involucrata. HQT is designed to alleviate joint swelling and pain, improve joint function, and modulate inflammation. Mechanistically, studies suggest HQT attenuates RA by upregulating miR-125b, which suppresses NF-κB-induced inflammation by targeting casein kinase II (CK2), and by regulating gut microbiota and bone metabolism. It has been evaluated in clinical trials in combination with methotrexate (MTX) for active rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huayu Qiangshen Tongbi Formula.